BHCM
AKBA icon

Brevan Howard Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Brevan Howard Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.2K Sell
26,021
-210,610
-89% -$289K ﹤0.01% 2105
2025
Q4 		$381K Buy
236,631
+158,510
+203% +$332K ﹤0.01% 1244
2025
Q3 		$213K Buy
78,121
+60,973
+356% +$203K ﹤0.01% 1720
2025
Q2 		$62.4K Buy
+17,148
New +$47.1K ﹤0.01% 1803
2024
Q2 		– Sell
-81,676
Closed -$149K – 1036
2024
Q1 		$149K Buy
+81,676
New +$131K ﹤0.01% 848

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Brevan Howard Capital Management's AKBA Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Akebia Therapeutics (AKBA) stake by 89% in Q1 2026, selling an estimated $289K and leaving 26,021 shares worth $36.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2105.

Brevan Howard Capital Management first reported a position in AKBA in Q1 2024 and has held it in 5 quarters since. The position peaked at $381K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Brevan Howard Capital Management held 26,021 shares of Akebia Therapeutics worth $36.2K as of Q1 2026.
  • Brevan Howard Capital Management sold 210,610 Akebia Therapeutics shares in Q1 2026, an estimated $289K.
  • Akebia Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2105 holding.
  • Brevan Howard Capital Management first reported a position in Akebia Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Brevan Howard Capital Management's Akebia Therapeutics position peaked at $381K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.